SCHEMBL13087754

SCHEMBL13087754

N#Cc1cc(-c2cc(NC3CCN(S(=O)(=O)C4CC4)CC3)c3cnccc3c2)ccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.38
CCNA2 P20248 2/20 0.38
CCR6 P51684 6/20 0.36
CCNT1 O60563 1/20 0.36
CDK1 P06493 1/20 0.36
CDK4 P11802 1/20 0.36
CCNB1 P14635 1/20 0.36
CCND1 P24385 1/20 0.36
CCNE1 P24864 1/20 0.36
CCND3 P30281 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36
CCNH P51946 1/20 0.36
MNAT1 P51948 1/20 0.36
CDK6 Q00534 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
JAK1 P23458 1/20 0.35
PRKD1 Q15139 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13087586 0.91 DYRK1A (0.43) CDK2CCNA2CCR6CCNT1CDK1
SCHEMBL13087584 0.90 IKBKB (0.40) CDK2CCNA2CCR6CCND1CCNE1
SCHEMBL13087372 0.89 CCR6 (0.40) CDK2CCNA2CCR6CCNT1CDK1
SCHEMBL13087291 0.87 CYP17A1 (0.43) CDK2CCND1CCNE1CDK6CYP11B1
SCHEMBL13087292 0.86 CYP17A1 (0.39) CCNT1CDK9CYP11B1JAK1PRKD1
SCHEMBL13087593 0.86 TLR8 (0.42) CDK2CCND1CCNE1CDK6JAK1
SCHEMBL13087490 0.86 CCR6 (0.46) CDK2CCNA2CCR6CCNT1CDK1
SCHEMBL13089969 0.86 ROCK2 (0.43) CDK2CCNA2CCR6CYP11B1CYP11B2
SCHEMBL13087496 0.85 CCNT1 (0.38) CDK2CCNA2CCR6CCNT1CDK1
SCHEMBL13087851 0.85 CNR1 (0.37) CCNT1CDK9CYP11B1JAK1PRKD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 CDK2 193/4885CCNA2 920/4885CCR6 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.